Event Announcement: VIROFIGHT Hybrid Symposium
One document
more
Stories about Medikament
- 2
Fundació Puigvert validates a new tool capable of selecting the most suitable antibiotic for uncomplicated urinary tract infections within 45 minutes.
One documentmore - 2
Record financing rounds at the Munich biotech hub
One documentmore canSERV relaunches Open Call for Service Provision
One documentmorePress release: STADA continues strong growth journey in the first half of 2024
One documentmore- 4
Sysmex’s PA-100 AST System Wins One of the UK’s Biggest Science Prizes
One documentmore Press release: Alvotech and STADA add to strategic alliance through denosumab partnership
Alvotech and STADA add to strategic alliance through denosumab partnership - STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central Asia and the Middle ...
One documentmorePress release: STADA welcomes CHMP positive opinion on extending indication for Kinpeygo
STADA welcomes CHMP positive opinion on extending indication for Kinpeygo - The CHMP adopted a positive opinion recommending a change to the terms of the marketing authorization of Kinpeygo for the treatment of adults with primary immunoglobulin A, now covering patients with a UPCR of ≥0.8 g/g - ...
One documentmorePress release: Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK
Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK - Bio-Thera and STADA have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® ...
One documentmorecanSERV invites applications for "Revolutionising Cancer Patient Care"
One documentmore- 3
canSERV invites applications for "Revolutionising Cancer Patient Care"
One documentmore Press release: STADA continues with double-digit sales and profit growth in 2023
One documentmore- 2
PM: DHL Global Forwarding transportiert für kinderherzen die weltweit erste mobile Herzklinik nach El Salvador / PR: DHL Global Forwarding supports NGO kinderherzen to deliver world’s first mobile heart clinic to El Salvador
2 Documentsmore Leipzig Tourismus und Marketing GmbH
5Pioneering Heart Surgery and Medical Congresses in Leipzig
One documentmorePress release: STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara - Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within ...
One documentmorePress release: Zuellig Pharma becomes STADA Philippines’ exclusive distribution partner
One documentmore- 3
EU Provides 1 Mio. to Researchers to Advance Personalised Oncology
One documentmore - 2
Press release : People with Parkinson’s experience variations in effects of oral medicines, but lack advice, international survey reveals
One documentmore - 2
Press release: STADA's excellent results in H1 2023 indicate a record annual profit of €1 bn, driven by Consumer Healthcare and Specialty
One documentmore Press release: STADA and Xbrane launch ranibizumab to support patient access in Europe
STADA and Xbrane launch ranibizumab to support patient access in Europe - Ranibizumab biosimilar is being launched in major European markets - Ranibizumab is the first product brought to market through a strategic collaboration between STADA and Xbrane, marking Xbrane’s first commercial launch and ...
One documentmore- 5
Press Release - hubergroup India expands its support for rural healthcare
One documentmore Press release: STADA sustains strong momentum with double-digit sales and profit growth in 2022
One documentmoreFree Access to Cancer Research Services - canSERV 1st Call for Proposals
One documentmoreInnovation and Start-up Center Biotechnology (IZB) welcomes Invitris
One documentmorePress release: EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab) - Partners Alvotech and STADA have marketing authorization application (MAA) for ustekinumab accepted for filing by the European Medicines Agency (EMA) ...
One documentmoreAM plays to its strengths in the medical field
One documentmore
1